Displaying drugs 13926 - 13950 of 15156 in total
ALT-P1
ALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.
Investigational
TRK-250
TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1) messenger RNA.
Investigational
Adze-1.17-CD40L
Investigational
ASP-7317
ASP-7317 consists of human embryonic stem cell-derived retinal pigment epithelium cells.
Investigational
Modified Cholera toxin A subunit
Investigational
Modified Cholera toxin B subunit
Investigational
PVX-410 component XBP1 SP367-375 (YLFPQLISV)
Investigational
PVX-410 component CS1 239-247(SLFVLGLFL)
Investigational
BJ-001
BJ-001 is a recombinant human interleukin-15/IL-15 receptor alpha complex with linked integrin-binding motif.
Investigational
Recombinant human placental growth factor (PLGF-131)
Investigational
GYM329
GYM329 is a recombinant humanized IgG1-based monoclonal antibody which binds to human latent myostatin in a pH-dependent manner
Investigational
AOC 1001
AOC 1001 is an antibody oligonucleotide conjugate (AOC), comprised of a human transferrin receptor 1 (TfR1) targeting, effector function null, humanized IgG1 antibody (AV01mAb) conjugated to one small interfering RNA (siRNA).
Investigational
ABBV-011
ABBV-011 is an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicin.
Investigational
C-CAR039
C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.
Investigational
CYNK-101
CYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).
Investigational
CLZ-2002
CLZ-2002 consists of allogeneic mesenchymal stem cells derived neuronal regeneration-promoting cells.
Investigational
MT-401
MT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy.
Investigational
MBX-2109
MBX-2109 is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.
Investigational
HG004
Investigational
BG1805
BG1805 is an investigational anti-CLL1 chimeric antigen receptor (CAR) T-cell therapy.
Investigational
Autologous adipose-derived stromal vascular fraction cells
Investigational
Recombinant human insulin-like growth factor 1
Investigational
Rovaleucel
Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.
Investigational
Displaying drugs 13926 - 13950 of 15156 in total